We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Invicro Acquires Imanova to Expand Global Imaging Capabilities

By MedImaging International staff writers
Posted on 19 Sep 2017
Print article
Invicro, LLC (Boston, MA, USA), a provider of imaging services and software for research and drug development, has acquired Imanova (London, UK), a translational research company that specializes in applying positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning techniques to improve productivity in early drug development and to help improve disease understanding. Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.

Invicro focuses on improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. The company provides a full range of image informatics, engineering and operational services. Through its preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers.

Imanova, an alliance between the UK's Medical Research Council, Imperial College London, King's College London and University College London, acts as a conduit between academia and industry. Imanova is among the leading players in the application of PET and MR imaging, with a focus on translational research to support the transition from pre-clinical studies to Phase I/II studies in humans. The services of the combined business cover the entire translational spectrum, ranging from novel biomarker evaluation and development in early discovery to late-phase clinical trials support.

The addition of Imanova is part of Invicro’s ongoing growth strategy to realize its mission to improve therapeutic discovery and development efforts through visualizing and quantifying biological and pathological processes in order to better diagnose, characterize, prevent, treat and, ultimately, cure disease.

“Joining forces with the phenomenal research team at Imanova expands our translational, analytic and geographic offering. Our groups share a common mission of improving research trials through the development and application of quantitative imaging biomarkers,” said Dr. Jack Hoppin, Invicro’s Co-Founder and CEO. “Our combined research teams hold a collective pride in the development of novel offerings in discovery as well as the engineering of scalable, reproducible solutions for deployment in late-phase development.”

“Invicro develops innovative analytical approaches for clinical trials, which are highly complementary with our own. Combining Invicro’s and Imanova’s analytics platforms means we have a best-in-class imaging informatics team to help reduce risk in drug development,” said Dr. Kevin Cox, Imanova’s CEO. “As a combined enterprise we will be a truly translational quantitative biomarker company, with an expanding late-phase clinical trial offering, able to meet the needs of a growing global market.”

Related Links:
Invicro
Imanova
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Dose Calibration Electrometer
PC Electrometer
Under Table Shield
3 Section Double Pivot Under Table Shield
Laptop Ultrasound Scanner
PL-3018

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The Cinematic Reality app enables interaction with realistic renderings of human anatomy (Photo courtesy of Siemens)

AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning

Siemens Healthineers (Erlangen, Germany) has launched an app designed for Apple Vision Pro that allows users including surgeons, medical students, or patients to view immersive, interactive holograms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.